Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-17T06:20:20.730Z Has data issue: false hasContentIssue false

Cholecystokinin and panic disorder

Published online by Cambridge University Press:  24 June 2014

Michel Bourin*
Affiliation:
EA 3256 “Neurobiologie de l'Anxiété et de la Dépression”, Faculté de Médecine, Nantes cedex 1, France
Eric Dailly
Affiliation:
EA 3256 “Neurobiologie de l'Anxiété et de la Dépression”, Faculté de Médecine, Nantes cedex 1, France
*
Michel Bourin, EA 3256 “Neurobiologie de l'Anxiété et de la Dépression”, Faculté de Médecine, BP 53508, Nantes cedex 1, France. Tel: +33-2-40412852; Fax: +33-2-40412856; E-mail: mbourin@sante.univ-nantes.fr

Abstract

Evidence for implication of cholecystokinin (CCK) in the neurobiology of panic disorder is reviewed through animal and human pharmacological studies. The results of these investigations raise two issues: (i) selectivity of action of CCK-2 agonists in anxiety disorders; and (ii) aberrations of the CCK system in anxiety disorders, both of which are discussed.

Information

Type
Review Article
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable